Former Incyte, Proteome Executive Joins Mechanism Discovery Company
Wednesday October 29, 9:00 am ET CAMBRIDGE MA - Genstruct Inc., a biotechnology company that develops conceptual biological models to determine compound mechanisms of action and identify biomarkers for drug discovery and development, today announced the appointment of Sharan A. Pagano as Vice President, Business Development & Alliances.
"I am very pleased to welcome Sharan to the Genstruct management team. She has been key in building the success of several groundbreaking biotechnology companies, including Genetics Institute, Proteome, and Incyte," said Keith O. Elliston, Ph.D., President and Chief Executive Officer of Genstruct. "Sharan's skill and depth of experience add the elemental management strength Genstruct needs to develop partnerships to commercialize its mechanism discovery framework."
Ms. Pagano brings to Genstruct 19 years of experience in the biotechnology and pharmaceutical industries, including business development, international sales and marketing, and product and process sciences. She joins Genstruct from Incyte Corporation, where she held management positions in Business Development and Strategic Collaborations. After the Incyte acquisition of Proteome, as Senior Director of Business Development and Marketing reporting to the CEO, Ms. Pagano built the Sales and Marketing operation and played a critical role in growing revenues, setting strategic priorities, and establishing collaborations.
During her tenure at Genetics Institute Ms. Pagano held several key positions, including Manager in Emerging Businesses, and participated in the development of DiscoverEase, a genomics based discovery business. As a Principal Scientist in the Process Development organization, she advanced to positions of increased scope and responsibility and pioneered the development of clinical and commercial cell culture processes for protein therapeutic products now marketed by Wyeth. Ms. Pagano received her B.S. in Biology from Merrimack College and her M.S. in Pharmaceutical Cell Biology from the University of Minnesota.
Founded in 2001, Genstruct is a therapeutic mechanism discovery company that has developed a platform for compound mechanism of action (MOA) and biomarker discovery called Molecular Epistemics™. This platform is comprised of two core technologies that enable the modeling and analysis of compound MOA, Knowledge Assembly™ and the Epistemics Engine™. Genstruct is developing discovery and development partnerships that apply Molecular Epistemics™ to accelerate discovery and approval and increase the output of drug discovery and development programs. The Company was co-founded by Flagship Ventures, based in Cambridge, MA. For more information visit www.genstruct.com.
For additional information regarding this announcement, please contact:
Director Strategic Marketing, Genstruct Inc.